Cite

    Vencio, S. et al. (2022). A randomized pharmacokinetic and pharmacodynamic trial of two regular human insulins demonstrates bioequivalence in type 1 diabetes and availability of biosimilar insulin may improve access to this medication. Diabetes, obesity & metabolism. 24 (8), pp. 1544-1552. [Online].